Last reviewed · How we verify
NCT05667077
The Effect of Amantadine on Post-COVD-19 Fatigue
Phase 2 trial testing Amantadine in Post-COVID-19 Syndrome in 83 participants. Status unknown.
29 December 2022
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 83 |
| Start date | 26 December 2022 |
| Primary completion | 29 December 2022 |
| Estimated completion | 10 January 2023 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Amantadine (AMANTADINE) — full drug profile →
Conditions studied
- Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
Adults 20 to 50, any sex, with Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to investigate amantadine's safety and its effect on reducing post-COVID-19 fatigue.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigue.
Harandi AA, Pakdaman H, Medghalchi A, Kimia N, et al · · 2024 · cited 12× · PMID 38228731 · DOI 10.1038/s41598-024-51904-z
Verify or expand the search:
- PubMed search for NCT05667077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Amantadine
Trials testing the same drug.
- NCT07113015 — A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease · NA · completed
- NCT06055244 — Amantadine Therapy for Cognitive Impairment in Long COVID · Phase 2 · completed
- NCT05479032 — Amantadine for Neuroenhancement in Acute Patients Study · Phase 2 · unknown
- NCT05140148 — Promoting Recovery After STroke With Amantadine · Phase 2 · recruiting
- NCT04936126 — Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression · Phase 4 · unknown
Other recruiting trials for Post-COVID-19 Syndrome
Currently open trials in the same condition.
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06231238 — Balance Acceptance and Commitment Therapy for Long COVID · NA · active not recruiting
- NCT06042751 — Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom · NA · active not recruiting
- NCT06073002 — Effects of a Home-Based Exercise Intervention in Subjects with Long COVID · NA · active not recruiting
- NCT05890599 — Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome · NA · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05667077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 28 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing